Narrow search
Showing 1 - 10 of 76,843
Cover Image
Evaluation of the Cost Effectiveness of Escitalopram versus Venlafaxine XR in Major Depressive Disorder
Fernandez, Jose-Luis; Montgomery, Stuart; Francois, Clement - In: PharmacoEconomics 23 (2005) 2, pp. 155-167
Aim: To assess the relative cost effectiveness of escitalopram compared with venlafaxine XR in patients with major … clinical trial and examined the costs and quality of life of 251 patients taking escitalopram versus venlafaxine. Outpatients … fulfilling criteria for MDD were randomised to receive oral escitalopram 10-20 mg/day or venlafaxine 75-150 mg/day for 8 weeks …
Persistent link: https://www.econbiz.de/10004990327
Cover Image
Use of Bayesian Net Benefit Regression Model to Examine the Impact of Generic Drug Entry on the Cost Effectiveness of Selective Serotonin Reuptake Inhibitors in Elderly Depressed P...
Shih, Ya-Chen Tina; Bekele, Nebiyou B.; Xu, Ying - In: PharmacoEconomics 25 (2007) 10, pp. 843-862
) have become the primary form of pharmaceutical treatment for depression. As the patents of several top-selling SSRIs have … compared the cost effectiveness of sertraline, citalopram, escitalopram and fluoxetine with paroxetine in elderly depressed … of generic paroxetine, and that, after the entry of generic paroxetine, citalopram and escitalopram were dominated by …
Persistent link: https://www.econbiz.de/10005449194
Cover Image
Tapering Off Benzodiazepines in Long-Term Users: An Economic Evaluation
Oude Voshaar, Richard C.; Krabbe, Paul F.M.; Gorgels, … - In: PharmacoEconomics 24 (2006) 7, pp. 683-694
Background: Discontinuation of benzodiazepine usage has never been evaluated in economic terms. This study aimed to compare the relative costs and outcomes of tapering off long-term benzodiazepine use combined with group cognitive behavioural therapy (TO+CBT), tapering off alone (TOA) and usual...
Persistent link: https://www.econbiz.de/10005243152
Cover Image
Cost Effectiveness of Ciprofloxacin plus Metronidazole versus Imipenem-Cilastatin in the Treatment of Intra-Abdominal Infections
Walters, Daniel J.; Solomkin, Joseph S.; Paladino, Joseph A. - In: PharmacoEconomics 16 (1999) 5, pp. 551-561
Objective: To compare the cost effectiveness of sequential intravenous (IV) to oral ciprofloxacin plus metronidazole (CIP/MTZ IV/PO) with that of IV ciprofloxacin plus IV metronidazole (CIP/MTZ IV) and IV imipenem-cilastatin (IMI IV) in patients with intra-abdominal infections. Design and...
Persistent link: https://www.econbiz.de/10005243176
Cover Image
Sample Size Determination for Cost-Effectiveness Trials
Willan, Andrew R. - In: PharmacoEconomics 29 (2011) 11, pp. 933-949
Methods for determining sample size requirements for cost-effectiveness studies are reviewed and illustrated. Traditional methods based on tests of hypothesis and power arguments are given for the incremental cost-effectiveness ratio and incremental net benefit (INB). In addition, a full...
Persistent link: https://www.econbiz.de/10010614384
Cover Image
Simvastatin After Orthotopic Heart Transplantation: Costs and Consequences
Krobot, Karl J.; Wenke, Klaus; Reichart, Bruno - In: PharmacoEconomics 15 (1999) 3, pp. 279-289
Objective: Recent data indicate that the combination of a low cholesterol diet and simvastatin following heart transplantation is associated with significant reduction of serum cholesterol levels, lower incidence of graft vessel disease (GVD) and significantly superior 4-year survival rates than...
Persistent link: https://www.econbiz.de/10005449010
Cover Image
Cost Effectiveness of Budesonide/Formoterol for Maintenance and Reliever Therapy versus Salmeterol/Fluticasone plus Salbutamol in the Treatment of Asthma
Johansson, Gunnar; Andreasson, Emma B.; Larsson, Per E.; … - In: PharmacoEconomics 24 (2006) 7, pp. 695-708
Introduction: Budesonide/formoterol (Symbicort(R)) Maintenance And Reliever Therapy (SMART) is an effective and well tolerated treatment option for patients with asthma. We compared the cost effectiveness from a societal perspective of this one-inhaler regimen with that of maintenance...
Persistent link: https://www.econbiz.de/10005449153
Cover Image
Cost Effectiveness of Helicobacter pylori Eradication Therapies in Patients with Duodenal Ulcer: An Analysis of Triple Therapy Versus Two Dual Therapy Alternatives
Tennvall, Gunnel R.; Norinder, Anna; Ohlin, Bo - In: PharmacoEconomics 16 (1999) 3, pp. 297-306
Objective: Recent research has focused on eradication therapy as the principal treatment of patients with duodenal ulcers and Helicobacter pylori infection. The aim of this study was to analyse the cost effectiveness of triple therapy versus 2 dual therapies. Design: A health economic evaluation...
Persistent link: https://www.econbiz.de/10005449162
Cover Image
A 1-Year Prospective Cost-Effectiveness Analysis of Roflumilast for the Treatment of Patients with Severe Chronic Obstructive Pulmonary Disease
Rutten-van Molken, Maureen P.M.H.; van Nooten, Floortje E. - In: PharmacoEconomics 25 (2007) 8, pp. 695-711
Rationale: Roflumilast is an oral, once-daily phosphodiesterase IV (PDE4) inhibitor under investigation for chronic obstructive pulmonary disease (COPD). This study investigated the cost effectiveness of roflumilast in patients with severe to very severe COPD from the perspective of the UK...
Persistent link: https://www.econbiz.de/10005449249
Cover Image
Cost-Effectiveness Analysis of Formoterol Versus Salmeterol in Patients with Asthma
Rutten-van Molken, Maureen P.M.H.; van Doorslaer, Eddy K.A. - In: PharmacoEconomics 14 (1998) 6, pp. 671-684
Objective: The aim of this study was to determine the relative economic consequences of treating asthmatics with twice daily dry powder formoterol 12microg as compared with salmeterol 50microg from a societal perspective. Design and Setting: A randomised, 6-month, open-label study including 482...
Persistent link: https://www.econbiz.de/10005404819